Definitions
Sorry, no definitions found. You may find more data at symphogen.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word Symphogen.
Examples
-
Symphogen also appointed Goran Ando -- former chief executive of British group Celltech, now part of UCB
UPDATE 1-Denmark's Symphogen raises $131 million, eyes IPO | Reuters 2011
-
SOBIV.ST but the group handed rights back to Symphogen last month after deciding it could no longer afford to continue developing the early-stage medicine.
UPDATE 1-Denmark's Symphogen raises $131 million, eyes IPO | Reuters 2011
-
The new money will help Symphogen accelerate development of its leading cancer drug candidate Sym004, which started early-stage clinical development last April.
UPDATE 1-Denmark's Symphogen raises $131 million, eyes IPO | Reuters 2011
-
LONDON, Jan 6 (Reuters) - Danish antibody drug developer Symphogen raised 100 million euros ($131 million) in the largest ever financing for a private European biotech company, giving it a cash cushion ahead of an eventual public listing.
UPDATE 1-Denmark's Symphogen raises $131 million, eyes IPO | Reuters 2011
-
The cash gives Symphogen flexibility as it considers its options for an initial public offering IPO.
UPDATE 1-Denmark's Symphogen raises $131 million, eyes IPO | Reuters 2011
-
"Our team at South Texas Accelerated Research Therapeutics (START) in San Antonio is very excited to work with Symphogen on the first clinical trial of the Sym004 in cancer patients," said Dr. Anthony Tolcher, Director of Clinical Research at START.
THE MEDICAL NEWS Editors 2010
-
"Our team at South Texas Accelerated Research Therapeutics (START) in San Antonio is very excited to work with Symphogen on the first clinical trial of the Sym004 in cancer patients," said Dr. Anthony Tolcher, Director of Clinical Research at START.
THE MEDICAL NEWS Editors 2010
-
Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors.
THE MEDICAL NEWS Editors 2010
-
Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors.
THE MEDICAL NEWS Editors 2010
-
"Our team at South Texas Accelerated Research Therapeutics (START) in San Antonio is very excited to work with Symphogen on the first clinical trial of the Sym004 in cancer patients," said Dr. Anthony Tolcher, Director of Clinical Research at START.
THE MEDICAL NEWS Editors 2010
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.